Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 727-733

  Conti, Fabio ^a   Buonfiglioli, Federica ^a   Scuteri, Alessandra ^b   Crespi, Cristina ^b   Bolondi, Luigi ^a   Caraceni, Paolo ^a   Foschi, Francesco Giuseppe ^c   Lenzi, Marco ^a   Mazzella, Giuseppe ^a   Verucchi, Gabriella ^a   Andreone, Pietro ^a   Brillanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Ospedale di Faenza   (Italy)

Author keywords

Cancer immunosurveillance; Cirrhosis; Direct Acting antivirals; HCC development; HCC occurrence; HCC prevention; HCC recurrence; Hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Interferon free therapy; Sustained virological response

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CHILD PUGH SCORE; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; VIRAL CLEARANCE; CHRONIC HEPATITIS C; LIVER TUMOR; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL;

EID: 84979702707     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.015     Document Type: Article

References (27)

1. [1] Seeff, L.B., Natural history of chronic hepatitis C. Hepatology 36 (2002), 35–46.
2. [2] Thein, H.H., Yi, Q., Dore, G.J., et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48 (2008), 418–431.
3. [3] Sangiovanni, A., Del Ninno, E., Fasani, P., et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126 (2004), 1005–1014.
4. [4] Lok, A.S., Seeff, L.B., Morgan, T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009), 138–148.
5. [5] Fried, M.W., Shiffman, M.L., Reddy, K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002), 975–982.
6. [6] von Wagner, M., Huber, M., Berg, T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129 (2005), 522–527.
7. [7] Veldt, B.J., Heathcote, E.J., Wedemeyer, H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007), 677–684.
8. [8] Morgan, R.L., Baack, B., Smith, B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
9. [9] El-Serag, H.B., Kanwal, F., Richardson, P., et al. Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCV-infection. Hepatology, 2016 [Epub ahead of print].
10. [10] Bourlière, M., Bronowicki, J.P., de Ledinghen, V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15 (2015), 397–404.
11. [11] Charlton, M., Everson, G.T., Flamm, S.L., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
12. [12] Leroy, V., Angus, P., Bronowicki, J.P., et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 63 (2016), 1430–1441.
13. [13] Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853.
14. [14] Fattovich, G., Giustina, G., Degos, F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997), 463–472.
15. [15] Goossens, N., Hoshida, Y., Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol 21 (2015), 105–114.
16. [16] Morgan, T.R., Ghany, M.G., Kim, H.Y., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (2010), 833–844.
17. [17] Ryerson, A.B., Eheman, C.R., Altekruse, S.F., et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122 (2016), 1312–1337.
18. [18] Manns, M., Samuel, D., Gane, E.J., et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis, 2016 [Epub ahead of print].
19. [19] Toyoda, H., Kumada, T., Tada, T., Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology, 2016, 10.1002/hep.28632 [Epub ahead of print].
20. [20] D'Ambrosio, R., Della Corte, C., Colombo, M., Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci 16 (2015), 19698–19712.
21. [21] Lencioni, R., Crocetti, L., Local-regional treatment of hepatocellular carcinoma. Radiology 262 (2012), 43–58.
22. [22] Pompili, M., Saviano, A., de Matthaeis, N., et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3 cm. Results of a multicenter Italian survey. J Hepatol 59 (2013), 89–97.
23. [23] M. Reig Z. Mariño, Perelló, C., et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
24. [24] Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
25. [25] Smyth, M.J., Dunn, G.P., Schreiber, R.D., Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006), 1–50.
26. [26] Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
27. [27] Spaan, M., van Oord, G., Kreefft, K., et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 213 (2016), 216–223.